2024-512403-39-01招募中1 期
A study to test a new immunotherapy, ABX-001, alone and in combination with the marketed drug, pembrolizumab, for the treatment of tumors previously treated with other therapies.
Abalos Therapeutics GmbH5 个研究点 分布在 2 个国家目标入组 27 人开始时间: 2025年9月22日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 27
- 试验地点
- 5
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
Senior Director Clinical Operations
Scientific
Abalos Therapeutics GmbH
研究点 (5)
Loading locations...
相似试验
招募中
1 期
A Study Testing the Investigational Drug XmAb541 in people with Advanced Cancer2025-521981-90-00Xencor Inc.70
撤回
1 期
A study to test a new immunotherapy, ABX-001, alone and in combination with the marketed drug, pembrolizumab, for the treatment of tumors previously treated with other therapies.2024-512403-39-00Abalos Therapeutics GmbH27
招募中
1 期
Phase I study to evaluate safety and immunogenicity of V-212 in healthy adult volunteers.2024-516008-41-00Virometix AG60
撤回
1 期
Phase I-Ib clinical trial of safety and immunobiology of prophylactic infusion of lymphocytes and NK cells after Allo-HCT.graft-versus-host disease2024-517002-28-00Red De Apoyo A La Investigacion Clinica En Hematologia Y Hemoterapia S.L., Vall D Hebron Institute Of Oncology8
招募中
1 期
A study to assess the safety and immunogenicity of a therapeutic hepatitis B virus vaccine, in healthy adults (RUBY).Hepatitis B2025-521169-28-00AstriVax16